AptaBio Therapeutics (293780 KS) announced positive topline data for European phase 2 clinical trial of its lead candidate, APX-115, which is being developed for the treatment of diabetic nephropathy.
Future progress of APX-115 in clinical trial will depend much on AptaBio’s capacity to enter a licensing deal for APX-115 with global pharmaceutical companies.
The company’s other pipeline drugs are also progressing, thereby keeping R&D expenditures at elevated level. However, the company’s current cash balance is not sufficient fund its R&D expenditures for long-term.
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network